Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pirtobrutinib - Loxo Oncology

Next Previous
Drug Profile

Pirtobrutinib - Loxo Oncology

Alternative Names: Jaypirca; LOXO-305; LY 3527727; RXC-005

Latest Information Update: 10 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Redx Pharma
  • Developer Eli Lilly and Company; Loxo Oncology
  • Class Amides; Amines; Antineoplastics; Fluorobenzenes; Pyrazoles; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Phase II Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Phase I/II Marginal zone B-cell lymphoma
  • Phase I Haematological malignancies

Most Recent Events

  • 27 Mar 2024 Loxo Oncology and Eli Lilly and Company withdrew a phase II trial prior to enrollment, in Multiple sclerosis (In adults) in USA and Puerto Rico (PO), due to a sponsor decision (NCT06104683)
  • 11 Dec 2023 Efficacy and adverse events data from a phase I/II BRUIN trial in Chronic lymphocytic leukaemia and Non-Hodgkin lymphoma released by Eli Lilly and Company
  • 09 Dec 2023 Efficacy and adverse events data from a phase II trial in Non-Hodgkin's lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top